research use only

Astaxanthin PPAR modulator

Cat.No.S3834

Astaxaxanthin (β-Carotene-4,4'-dione, Trans-Astaxanthin), a xanthophyll carotenoid, is a nutrient with unique cell membrane actions and diverse clinical benefits with excellent safety and tolerability. This compound, a red dietary carotenoid isolated from Haematococcus pluvialis, is a modulator of PPARγ and a potent antioxidant with antiproliferative, neuroprotective and anti-inflammatory activity.
Astaxanthin PPAR modulator Chemical Structure

Chemical Structure

Molecular Weight: 596.84

Quality Control

Chemical Information, Storage & Stability

Molecular Weight 596.84 Formula

C40H52O4

Storage (From the date of receipt)
CAS No. 472-61-7 Download SDF Storage of Stock Solutions

Synonyms β-Carotene-4,4'-dione, Trans-Astaxanthin Smiles CC1=C(C(CC(C1=O)O)(C)C)C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC2=C(C(=O)C(CC2(C)C)O)C)C)C

Solubility

In vitro
Batch:

DMSO : 6 mg/mL ( (10.05 mM) Warmed with 50°C water bath; Ultrasonicated; Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

In vitro
Astaxaxanthin is a carotenoid nutrient with molecular properties that precisely position it within cell membranes and circulating lipoproteins, thereby imbuing them with potent antioxidant and anti-inflammatory actions. This compound also effectively protects the double membrane system of mitochondria, to the point of boosting their energy production efficiency. In cultured cells, it protects the mitochondria against endogenous oxygen radicals, conserves their redox (antioxidant) capacity, and enhances their energy production efficiency. It has also protected human LDL against oxidative attack. This chemical specifically protects the mitochondria of cultured nerve cells against toxic attack and stimulates the proliferation of cultured nerve stem cells. It effectively protects cultured nerve cells against hydrogen peroxide toxicity, and down-regulates genes linked to cell death and up-regulates genes linked to cell survival[1].
In vivo
In pharmacokinetic studies, after ingestion of esterified natural astaxanthin, only unesterified astaxanthin appears in the blood. This compound's bioavailability is substantially affected by meal timing and by smoking. Supplementation with this chemical may lower lipid peroxidation in vivo. It significantly improves the memory performance of mice in the Morris water maze. It has demonstrated safety in numerous human clinical trials. The doses of this compound used in clinical trials have ranged from 1 mg/day to 40 mg/day (with the majority in the 6-12 mg range); single-dose pharmacokinetic studies use up to 100 mg per dose[1].
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05138549 Terminated
Osteoarthritis Knee|Osteoarthritis Knees Both|Joint Inflammation
Prisma Health-Midlands
September 2 2022 Phase 2|Phase 3
NCT05437601 Completed
Osteoarthritis Knee
Bangabandhu Sheikh Mujib Medical University Dhaka Bangladesh
July 31 2022 Phase 2
NCT05376501 Completed
Healthy
LycoRed Ltd.|Nutrasource Pharmaceutical and Nutraceutical Services Inc.
June 8 2022 Not Applicable
NCT02343497 Completed
Dyslipidemias
Ajinomoto Foods Europe SAS|Institut Polytechnique LaSalle Beauvais|Naturalpha
August 2014 Not Applicable
NCT03945526 Completed
Cerebral Stroke|Malondialdehyde|Oxidative Stress
Indonesia University
March 23 2010 Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Signaling Pathway Map